Revisiting Luteolin: An Updated Review on Its Anticancer Potential

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Mar 8

PMID 38455556

Authors

Abdur Rauf

Polrat Wilairatana

Payal B Joshi

Zubair Ahmad

Ahmed Olatunde

Nabia Hafeez

Hassan A Hemeg

Mohammad S Mubarak

Affiliations

Soon will be listed here.

Abstract

Numerous natural products found in our diet, such as polyphenols and flavonoids, can prevent the progression of cancer. Luteolin, a natural flavone, present in significant amounts in various fruits and vegetables plays a key role as a chemopreventive agent in treating various types of cancer. By inducing apoptosis, initiating cell cycle arrest, and decreasing angiogenesis, metastasis, and cell proliferation, luteolin is used to treat cancer. Its anticancer properties are attributed to its capability to engage with multiple molecular targeted sites and modify various signaling pathways in tumor cells. Luteolin has been shown to slow the spread of cancer in breast, colorectal, lung, prostate, liver, skin, pancreatic, oral, and gastric cancer models. It exhibits antioxidant properties and can be given to patients receiving Doxorubicin (DOX) chemotherapy to prevent the development of unexpected adverse reactions in the lungs and hematopoietic system subjected to DOX. Furthermore, it could be an excellent candidate for synergistic studies to overcome drug resistance in cancer cells. Accordingly, this review covers the recent literature related to the use of luteolin against different types of cancer, along with the mechanisms of action. In addition, the review highlights luteolin as a complementary medicine for preventing and treating cancer.

Citing Articles

Exploring the therapeutic potential of natural products in modulating miRNA networks in prostate cancer.

Mohammed O Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39976718 DOI: 10.1007/s00210-025-03898-2.

Telomerase in cancer- ongoing quest and future discoveries.

Mishra A, Patel T Mol Biol Rep. 2025; 52(1):161.

PMID: 39862360 DOI: 10.1007/s11033-025-10251-6.

Molecular Mechanisms of Dietary Compounds in Cancer Stem Cells from Solid Tumors: Insights into Colorectal, Breast, and Prostate Cancer.

Filippi A, Deculescu-Ionita T, Hudita A, Baldasici O, Galateanu B, Mocanu M Int J Mol Sci. 2025; 26(2).

PMID: 39859345 PMC: 11766403. DOI: 10.3390/ijms26020631.

Stimulation, regulation, and inflammaging interventions of natural compounds on nuclear factor kappa B (NF-kB) pathway: a comprehensive review.

Kannan G, Mathews Paul B, Thangaraj P Inflammopharmacology. 2025; 33(1):145-162.

PMID: 39776026 DOI: 10.1007/s10787-024-01635-4.

A Comprehensive Review of the Phytochemical Constituents and Bioactivities of .

Bhattarai K, Bhattarai R, Pandey R, Paudel B, Bhattarai H ScientificWorldJournal. 2024; 2024:8895039.

PMID: 39473808 PMC: 11521583. DOI: 10.1155/2024/8895039.

References

Chen Z, Zhang B, Gao F, Shi R . Modulation of G/M cell cycle arrest and apoptosis by luteolin in human colon cancer cells and xenografts. Oncol Lett. 2018; 15(2):1559-1565. PMC: 5776168. DOI: 10.3892/ol.2017.7475. View

Jez J, Bowman M, Dixon R, Noel J . Structure and mechanism of the evolutionarily unique plant enzyme chalcone isomerase. Nat Struct Biol. 2000; 7(9):786-91. DOI: 10.1038/79025. View

Majumdar D, Jung K, Zhang H, Nannapaneni S, Wang X, Amin A . Luteolin nanoparticle in chemoprevention: in vitro and in vivo anticancer activity. Cancer Prev Res (Phila). 2014; 7(1):65-73. PMC: 3888883. DOI: 10.1158/1940-6207.CAPR-13-0230. View

Kim Y, Kim Y, Choi I, Kim C, Lee J, Cho S . Long-term survival after endoscopic resection versus surgery in early gastric cancers. Endoscopy. 2015; 47(4):293-301. DOI: 10.1055/s-0034-1391284. View

Tsai P, Cheng C, Lin C, Huang Y, Lee L, Kandaswami C . Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells. Anticancer Res. 2016; 36(12):6367-6380. DOI: 10.21873/anticanres.11234. View

Ntalouka F, Tsirivakou A . Luteolin: A promising natural agent in management of pain in chronic conditions. Front Pain Res (Lausanne). 2023; 4:1114428. PMC: 10016360. DOI: 10.3389/fpain.2023.1114428. View

Rungsung S, Singh T, Rabha D, Kumar T, Lingaraju M, Parida S . Luteolin attenuates acute lung injury in experimental mouse model of sepsis. Cytokine. 2018; 110:333-343. DOI: 10.1016/j.cyto.2018.03.042. View

Song S, Su Z, Xu H, Niu M, Chen X, Min H . Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1. Cell Death Dis. 2017; 8(2):e2612. PMC: 5386483. DOI: 10.1038/cddis.2017.38. View

Zhang X, Wu C . , , and Evaluation of the Developmental Toxicity, Estrogenic Activity, and Mutagenicity of Four Natural Phenolic Flavonoids at Low Exposure Levels. ACS Omega. 2022; 7(6):4757-4768. PMC: 8851455. DOI: 10.1021/acsomega.1c04239. View

10.

Kang K, Piao M, Hyun Y, Zhen A, Cho S, Ahn M . Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells. Exp Mol Med. 2019; 51(4):1-14. PMC: 6465248. DOI: 10.1038/s12276-019-0238-y. View

11.

Tuli H, Rath P, Chauhan A, Sak K, Aggarwal D, Choudhary R . Luteolin, a Potent Anticancer Compound: From Chemistry to Cellular Interactions and Synergetic Perspectives. Cancers (Basel). 2022; 14(21). PMC: 9658186. DOI: 10.3390/cancers14215373. View

12.

Feng J, Zheng T, Hou Z, Lv C, Xue A, Han T . Luteolin, an aryl hydrocarbon receptor ligand, suppresses tumor metastasis in vitro and in vivo. Oncol Rep. 2020; 44(5):2231-2240. DOI: 10.3892/or.2020.7781. View

13.

Cho H, Ahn K, Choi J, Hwang S, Kim W, Um H . Luteolin acts as a radiosensitizer in non‑small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade. Int J Oncol. 2015; 46(3):1149-58. DOI: 10.3892/ijo.2015.2831. View

14.

Caporali S, De Stefano A, Calabrese C, Giovannelli A, Pieri M, Savini I . Anti-Inflammatory and Active Biological Properties of the Plant-Derived Bioactive Compounds Luteolin and Luteolin 7-Glucoside. Nutrients. 2022; 14(6). PMC: 8949538. DOI: 10.3390/nu14061155. View

15.

Jiang Z, Wang W, Xu C, Xie Y, Wang X, Zhang Y . Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer Lett. 2021; 515:36-48. DOI: 10.1016/j.canlet.2021.05.019. View

16.

Pandurangan A, Mohd Esa N . Luteolin, a bioflavonoid inhibits colorectal cancer through modulation of multiple signaling pathways: a review. Asian Pac J Cancer Prev. 2014; 15(14):5501-8. DOI: 10.7314/apjcp.2014.15.14.5501. View

17.

Gormaz J, Quintremil S, Rodrigo R . Cardiovascular Disease: A Target for the Pharmacological Effects of Quercetin. Curr Top Med Chem. 2015; 15(17):1735-42. DOI: 10.2174/1568026615666150427124357. View

18.

Han K, Lang T, Zhang Z, Zhang Y, Sun Y, Shen Z . Luteolin attenuates Wnt signaling via upregulation of FZD6 to suppress prostate cancer stemness revealed by comparative proteomics. Sci Rep. 2018; 8(1):8537. PMC: 5986741. DOI: 10.1038/s41598-018-26761-2. View

19.

Aziz N, Kim M, Cho J . Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies. J Ethnopharmacol. 2018; 225:342-358. DOI: 10.1016/j.jep.2018.05.019. View

20.

Li Z, Zhang Y, Chen L, Li H . The dietary compound luteolin inhibits pancreatic cancer growth by targeting BCL-2. Food Funct. 2018; 9(5):3018-3027. DOI: 10.1039/c8fo00033f. View